Hangzhou Aida Pharmaceuticals Co. Ltd.

(1) To preliminarily explore the efficacy and safety of high, medium and low doses of doxifluridine for injection in the treatment of advanced breast cancer and gastric cancer; (2) To observe the in vivo time course of the drug after single and multiple doses of intravenous infusion of doxifluridine for injection in patients with breast cancer, gastric cancer, etc., estimate its pharmacokinetic parameters, and compare them with the pharmacokinetic parameters of patients after intravenous infusion of 5-FU, so as to provide guidance for clinical drug use.